Ovarian and Peritoneal Malignancies
Research activity includes high-grade serous ovarian cancer, platinum-resistant ovarian cancer, and primary peritoneal cancer, with attention to treatment-resistant disease and antitumor activity in women with advanced gynecologic cancers.
- High-grade serous ovarian cancer
- Platinum-resistant ovarian cancer
- Primary peritoneal cancer
These programs focus on recurrent and persistent disease settings where new therapeutic options are needed.
Uterine Serous Carcinoma
The sponsor supports clinical research in recurrent or persistent uterine serous carcinoma, with emphasis on safety, tolerability, and tumor response in this aggressive endometrial cancer subtype.
- Recurrent uterine serous carcinoma
- Persistent uterine serous carcinoma
- Gynecologic oncology
Interest in this area reflects a focus on difficult-to-treat uterine malignancies with limited treatment options.
Metastatic Colorectal Cancer
Clinical studies in metastatic colorectal cancer address advanced solid tumor disease, including combination-based approaches and evaluation of antitumor activity in the metastatic setting.
- Metastatic colorectal cancer
- Advanced solid tumors
- Combination oncology therapy
This area adds a gastrointestinal oncology focus to the sponsor’s broader cancer research portfolio.
Cell-Cycle and DNA Damage Response Oncology
The funded trials center on ZN-c3 and azenosertib, with investigation of cell-cycle regulation, DNA damage response, and cyclin E1-positive tumor biology across resistant cancers.
- ZN-c3
- Azenosertib
- Cyclin E1-positive tumors
Research in this domain spans both monotherapy and combination therapy strategies in solid tumors.
